Across TCGA pan-cancer cohorts, ARHGEF37 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARHGEF37 data layer compared with 18 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARHGEF37 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARHGEF37 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.
HNSC, PDAC, and LUAD are the cancer types where ARHGEF37 mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.